Business
Merck’s COVID-19 pill cuts risk of death, hospitalisation by half in study – Sydney Morning Herald
Merck and partner Ridgeback Biotherapeutics plan to seek US emergency use authorisation for the pill as soon as possible.
Merck & Co Incs experimental oral drug for COVID-19, molnupiravir, reduced by around 50 per cent the chance of hospitalisation or death for patients at risk of severe disease, according to interim clinical trial results announced on Friday.
Merck and partner…
Continue Reading
-
General15 hours agoCampers evacuated, residents on alert as Moreton Island bushfire intensifies
-
Noosa News21 hours agoPerth Royal Show vendors upset by price hikes, say crowds are down in 2025
-
Business23 hours agoBell Potter names the best ASX shares to buy in October
-
General20 hours agoAustralia welcomes Gaza peace progress, hostage release